Linezolid

Linezolid, the active ingredient in Linezolid, is an oxazolidinone presented as an intravenous solution for IV use. It treats infections caused by resistant Gram‑positive bacteria in hospitalized patients.

GNH USA supplies Linezolid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolid is employed against serious Gram‑positive bacterial infections, particularly those resistant to other agents. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates the pathogen and resolves infection. - Vancomycin‑resistant Enterococcus (VRE) infections: provides effective bacterial clearance. - Skin and soft‑tissue infections caused by Gram‑positive bacteria: reduces lesion size and promotes healing. - Community‑acquired and hospital‑acquired pneumonia caused by susceptible organisms: improves respiratory function and clears infection.

Linezolid may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: persistent metallic sensation in the mouth. - Myelosuppression (thrombocytopenia): reduced platelet count.

Serious or Rare Side Effects: - Serotonin syndrome: potentially life‑threatening when combined with serotonergic agents. - Peripheral neuropathy: numbness or tingling in extremities. - Optic neuropathy: visual disturbances, possible vision loss. - Lactic acidosis: metabolic acidosis with elevated lactate. - Severe anemia: marked drop in hemoglobin levels. - Hyperlactatemia: elevated blood lactate without acidosis.

Before initiating Linezolid therapy, clinicians should consider several safety measures. - Monitor blood counts: regular CBC to detect myelosuppression. - Assess for serotonin syndrome: avoid concomitant serotonergic drugs. - Avoid use with MAO inhibitors: risk of hypertensive crisis. - Use caution in renal or hepatic impairment: adjust monitoring frequency. - Limit duration of therapy when possible: prolonged use increases risk of neuropathy. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increase risk of serotonin syndrome. - Sympathomimetic agents (e.g., pseudoephedrine): can cause hypertensive episodes.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing linezolid plasma levels. - Anticonvulsants (e.g., phenytoin): may lower linezolid concentrations. - Warfarin: potential increase in INR, requiring coagulation monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may enhance bleeding risk.